NasdaqGS - Delayed Quote • USD
Editas Medicine, Inc. (EDIT)
At close: 4:00 PM EDT
After hours: 5:26 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 16 | 16 |
| Avg. Estimate | -0.69 | -0.68 | -2.69 | -2.62 |
| Low Estimate | -0.84 | -0.88 | -3.37 | -3.46 |
| High Estimate | -0.46 | -0.25 | -1.84 | -1.72 |
| Year Ago EPS | -0.56 | -0.55 | -2.02 | -2.69 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 15 | 14 |
| Avg. Estimate | 5.19M | 5.58M | 31.09M | 23.45M |
| Low Estimate | -- | -- | 5M | -- |
| High Estimate | 14.7M | 14.7M | 64.54M | 37M |
| Year Ago Sales | 4.17M | 5.34M | 78.12M | 31.09M |
| Sales Growth (year/est) | 24.50% | 4.60% | -60.20% | -24.60% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.76 | -0.57 | -0.54 | -0.66 |
| EPS Actual | -0.56 | -0.55 | -0.23 | -0.76 |
| Difference | 0.2 | 0.02 | 0.31 | -0.1 |
| Surprise % | 26.30% | 3.50% | 57.40% | -15.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.69 | -0.68 | -2.69 | -2.62 |
| 7 Days Ago | -0.68 | -0.69 | -2.69 | -2.56 |
| 30 Days Ago | -0.67 | -0.69 | -2.66 | -2.74 |
| 60 Days Ago | -0.67 | -0.69 | -2.66 | -2.74 |
| 90 Days Ago | -0.59 | -0.62 | -2.35 | -2.34 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | -- | -- |
| Up Last 30 Days | 5 | 6 | 4 | 6 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 1 | 2 | 1 |
Growth Estimates
| CURRENCY IN USD | EDIT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -23.20% | -- | -- | 7.90% |
| Next Qtr. | -23.60% | -- | -- | 12.30% |
| Current Year | -33.20% | -- | -- | 5.70% |
| Next Year | 2.60% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 1.70% | -- | -- | 11.21% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 5/9/2024 |
| Upgrade | Morgan Stanley: Underweight to Equal-Weight | 5/9/2024 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 5/9/2024 |
| Maintains | Citigroup: Buy to Buy | 2/29/2024 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 2/29/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 2/27/2024 |
Related Tickers
NTLA Intellia Therapeutics, Inc.
25.89
-1.26%
BEAM Beam Therapeutics Inc.
24.84
+0.89%
CRSP CRISPR Therapeutics AG
55.47
-1.33%
CRBU Caribou Biosciences, Inc.
3.1300
-7.67%
BLUE bluebird bio, Inc.
1.0300
0.00%
VERV Verve Therapeutics, Inc.
5.95
-0.50%
PRME Prime Medicine, Inc.
7.53
+6.36%
DNA Ginkgo Bioworks Holdings, Inc.
0.7661
-4.90%
VRTX Vertex Pharmaceuticals Incorporated
445.87
+0.15%
IOVA Iovance Biotherapeutics, Inc.
10.35
+1.07%